Abstract

The tumor microenvironment (TME) comprises distinct cell types, including stromal types such as fibroblast cells and macrophage cells, which have recently become a critical factor in tumor development and progression. Here, we identified the TME-related gene, plexin domain containing 2 (PLXDC2), in a high-stromal-score population. And we revealed that this gene was related to poor survival and advanced (tumor-node-metastasis) stage in gastric cancer (GC) patients from The Cancer Genome Atlas database. An integrated gene profile and functional analysis of the proportions of tumor-infiltrating immune cells revealed that the expression of the M2 macrophages cell marker CD163 was positively correlated with PLXDC2 expression. In addition, the M2 macrophages gene signature and high PLXDC2 expression were associated with the inflammatory signaling pathway and the epithelial-to-mesenchymal transition (EMT)-related gene signature. Single-cell study of GC identified PLXDC2 was enriched specifically in fibroblasts and monocytes/macrophages populations, which supported its important role in the stroma. Furthermore, according to a tissue microarray immunohistochemistry analysis, the expression of PLXDC2 elevated in human GC stromal specimens compared to tumor tissue specimens. Moreover, PLXDC2 overexpression in the stromal compartment was associated with CD163-positive regulatory M2 macrophages, and its functions were related to the pathogenesis of GC. Multiplexed immunohistochemistry verified PLXDC2’s correlation with EMT markers. Our data suggested that PLXDC2 was expressed in stromal cells and that its crosstalk with tumor-associated macrophages could contribute to cancer biology by inducing the EMT process.

Highlights

  • Gastric cancer (GC) is one of the major causes of cancer-related mortality worldwide

  • Recent studies have proposed new treatment strategies based on disease risk stratification [tumor-nodemetastasis (TNM) stage] and histological grade according to tumor size, lymph node or distant metastasis ( AJCC system, T describes the size of the original tumor and whether it has invaded nearby tissue, N describes nearby lymph nodes that are involved, and M describes distant metastasis; Edge and Compton, 2010), the ability of these strategies to improve the prognosis of gastric cancer (GC) patients has been widely questioned

  • We focused on plexin domain containing 2 (PLXDC2), a gene that was not previously linked with GC

Read more

Summary

Introduction

Gastric cancer (GC) is one of the major causes of cancer-related mortality worldwide. It has been reported that 1.0337 million new GC cases and approximately 783,000 GC- related deaths occurred in 2018 (Bray et al, 2018; Siegel et al, 2021). This may be attributed to the high Helicobacter pylori (HP) infection rate (Hatakeyama, 2019; Kotilea et al, 2019). Molecular diagnosis has been previously proven to be effective. Discoveries of biomarkers, such as ERBB2 and EGFR, aid in informed treatment decision making by medical oncologists (Yasui et al, 2001). A study seeking novel GC molecular biomarkers might offer a solution to our current challenges

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call